ArticleDiscover oncology2025
Integration of exosome-related genes and differential expression analysis reveals potential biomarkers for prostate cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles in prostate cancer: current understanding and future perspectives.Journal of the National Cancer Center · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundProstate cancer (PCa) is a prevalent malignancy in men, with exosomes playing a key role in tumor microenvironment and disease progression, yet their molecular mechanisms remain unclear.This study aims to identify potential biomarkers and therapeutic targets in PCa by integrating exosome-related genes with differentially expressed genes (DEGs).
methodsFour GEO datasets (GSE32448, GSE46602, GSE69223, GSE6956) were analyzed. Batch effects were corrected using the ComBat method, followed by DEG analysis and feature selection via machine learning (LASSO regression, random forest, SVM). Functional enrichment and molecular docking validated the findings.
resultsPost-correction, sample clustering improved significantly. Of 49 overlapping DEGs and exosome-related genes, EEF2, LGALS3, and MYO1D emerged as key biomarkers, with EEF2 showing the highest predictive power (AUC = 0.786). A risk score model achieved an AUC of 0.886. Immune analysis linked these genes to immune cell subsets, and docking studies revealed strong interactions with small molecules like cycloheximide.
conclusionThis study elucidates the molecular role of exosome-related genes in PCa, proposing predictive biomarkers and novel therapeutic targets, warranting further clinical validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.